Blog Read the latest perspectives from our team of subject matter experts and others CEO Insights: Solving Healthcare’s Provider Data Challenge Through H1’s Acquisition of VedaToday, I’m proud to announce that H1 is acquiring Veda. This follows our acquisition of Ribbon Health in December 2024. By bringing in Veda’s suite of products, data, team, and… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact KOL Engagement Patient Representation Provider Data Post Industries:Digital Health Health Plans Pharmaceutical & Biotechnology Drug DevelopmentReal World Data: Sources and Effective EvaluationHelp you understand what real world data (RWD) is and how it is used. Discuss the many sources of RWD and how tracking and measuring RWD can be challenging.… Continue reading → Read the article KOL EngagementHow Physicians Are Compensated by Life Sciences CompaniesIt’s no secret that compensation for physicians consulting at pharmaceutical, device and life sciences firms is often much higher than what’s on the table at hospitals and university-affiliated medical centers.… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataFormer Dropbox CIO Joins Board of Healthcare Data Startup H1Board member Sylvie Veilleux (Salesforce, Dropbox), CFO Karen Moran (Alteryx, Domo) and CDO Mayur Thakur (Goldman Sachs, Google) bring decades of experience and add bench strength as H1 expands.… Continue reading → Read the article Drug DevelopmentPatient RepresentationThe Post-Pandemic Future of Clinical TrialsIn a post-COVID world, we’re seeing a decade’s worth of reshaping within clinical trials solidify in less than a year. While the life sciences industry was making a slow… Continue reading → Read the article CommercializationDrug DevelopmentPatient RepresentationWhy Patient Representation Matters for PharmaIt matters because inclusion and trust matter. When developing therapies and medications, pharmaceutical and life sciences companies are tasked with designing products for a diverse range of patients and… Continue reading → Read the article KOL EngagementWhy Physicians May Want to Become Key Opinion LeadersDuring drug development, life science companies often turn to healthcare professionals (HCPs) for input, advice and expertise. These HCPs advising companies are generally known as Key Opinion Leaders (KOLs), thought… Continue reading → Read the article«‹9101112131415›»
